ATAZANAVIR SULFATE
(ATAZANAVIRI SULFAS)

Draft revision for The International Pharmacopoeia

(March 2018)

DRAFT FOR COMMENT

Should you have any comments on this draft, please send these to Dr Herbert Schmidt, Medicines Quality Assurance Programme, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41 22) 791 4730 or email: schmidt@who.int by 11 May 2018.

In order to speed up the process for receiving draft monographs and for sending comments, please let us have your email address (to bonnyw@who.int) and we will add it to our electronic mailing list. Please specify if you wish to receive monographs.

© World Health Organization 2018
All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.

Please send any request for permission to:
Dr Sabine Kopp, Manager, Medicines Quality Assurance Programme, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland.
Fax: (+41-22) 791 4730; email: kopp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/17.38:

Draft revision for *The International Pharmacopoeia*

**ATAZANAVIR SULFATE**

**(ATAZANAVIRI SULFAS)**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>First draft received from collaborating laboratory</td>
<td>September 2017</td>
</tr>
<tr>
<td>Submission to the fifty-second meeting of the WHO Expert Committee on</td>
<td>16–20 October 2017</td>
</tr>
<tr>
<td>Specifications for Pharmaceutical Preparations</td>
<td></td>
</tr>
<tr>
<td>Draft revision sent out for public consultation</td>
<td>March–May 2018</td>
</tr>
<tr>
<td>Further follow-up action as required</td>
<td></td>
</tr>
</tbody>
</table>

[Note from the Secretariat: Following laboratory investigations performed to establish Atazanavir sulfate ICRS it is proposed to revise the monograph on Atazanavir sulfate with a view to:

- change the recrystallization solvent used in identity test A by IR (from methanol to acetone);
- update the style of the monograph.

Changes from the current monograph are indicated in the text by insert or delete.]
ATAZANAVIR SULFATE
(ATAZANAVIRI SULFAS)

Molecular formula. \( \text{C}_{38}\text{H}_{52}\text{N}_{6}\text{O}_{7} \cdot \text{H}_{2}\text{O}_{4}\text{S} \)

Relative molecular mass. 802.9

Chemical names. Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[[4-(pyridin-2-yl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate monosulfate; 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1); CAS 229975-97-7

Description. A white to a pale yellow powder.

Solubility. Freely soluble in methanol, practically insoluble in water.

Category. Antiretroviral (protease inhibitor).

Storage. Atazanavir sulfate should be kept in a tightly closed container.

Additional information. Atazanavir sulfate is slightly hygroscopic and may exhibit polymorphism.

Requirements

Atazanavir sulfate contains not less than 98.0% and not more than 102.0% of \( \text{C}_{38}\text{H}_{52}\text{N}_{6}\text{O}_{7} \cdot \text{H}_{2}\text{SO}_{4} \), calculated with reference to the dried substance.

Identity tests

- Either test A and D or test B, C and D should be applied.

A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from atazanavir sulfate RS or with the reference spectrum of atazanavir sulfate.
If the spectra thus obtained are not concordant repeat the test using the residues obtained by separately dissolving the test substance and atazanavir sulfate RS in a small amount of methanol acetone R and evaporating to dryness. The infrared absorption spectrum is concordant with the spectrum obtained from atazanavir sulfate RS.

B. Carry out test B.1, or where ultraviolet (UV) detection is not available, test B.2.

B.1 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R6 as the coating substance and a mixture of 9.5 volumes of dichloromethane R and 0.5 volume of 2-propanol R as the mobile phase. Apply separately to the plate 10 µL of each of the following 2 solutions in methanol R. For solution (A) use 1 mg of the test substance per mL. For solution (B) use 1 mg of atazanavir sulfate RS per mL. After removing the plate from the chromatographic chamber allow it to dry exhaustively in air or in a current of air. Examine the chromatogram in UV light (254 nm). The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

B.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using the conditions described under test B.1, but using a plate containing silica gel R5 as the coating substance.

Spray the plate with basic potassium permanganate (~5 g/L) TS. Examine the chromatogram in daylight. The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

C. The absorption spectrum of a 10 µg/mL solution of the test substance in methanol R, when observed between 230 nm and 340 nm, exhibits two maxima at about 250 nm and 280 nm.

D. A 20 mg/mL solution of the test substance yields reaction A described under 2.1 General identification tests as characteristic of sulfates.

Heavy metals. 2.2.3 Limit test for heavy metals

Sulfated ash (2.3). Not more than 2.0 mg/g.

Loss on drying. Dry for 3 hours at 105 °C; it loses not more than 10.0 mg/g.

Specific optical rotation. Use a 10 mg/mL solution in equal volumes of methanol R and water R at 22 °C and calculate with reference to the dried substance; the specific optical rotation is between -44° and -48°.
Related substances

Carry out the test as described under 1.14.4 High-performance liquid chromatography using a column (150 mm x 4.6 mm) packed with end-capped, base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm). Use the following conditions for gradient elution:

- mobile phase A: 0.02 M phosphate buffer pH 3.5, acetonitrile R (70:30 v/v);
- mobile phase B: 0.02 M phosphate buffer pH 3.5, acetonitrile R (30:70 v/v).

Prepare the 0.02 M phosphate buffer pH 3.5 by dissolving 2.72 g of anhydrous potassium dihydrogen phosphate R in 800 mL of water R, adjust the pH to 3.5 by adding phosphoric acid (~105 g/L) TS and dilute to 1000 mL with water R.

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>Mobile phase A (% v/v)</th>
<th>Mobile phase B (% v/v)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–2</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
<tr>
<td>2–10</td>
<td>100 to 75</td>
<td>0 to 25</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>10–30</td>
<td>75 to 50</td>
<td>25 to 50</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>30–45</td>
<td>50 to 0</td>
<td>50 to 100</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>45–50</td>
<td>0</td>
<td>100</td>
<td>Isocratic</td>
</tr>
<tr>
<td>50–52</td>
<td>0 to 100</td>
<td>100 to 0</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>52–60</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
</tbody>
</table>

Prepare the following solutions using as diluent a mixture of equal volumes of water R and acetonitrile R. For solution (1) dissolve about 50 mg of the test substance and dilute to 50.0 mL. For solution (1) use 1 mg of the test substance per mL. For solution (2) dilute 10.0 mL of solution (1) to 200.0 mL. Dilute 10.0 mL of this solution to 100.0 mL a suitable volume of solution (1) with the diluent to obtain a concentration equivalent to 5 μg of Atazanavir sulfate per mL. For solution (3) mix 1 mL of solution (1) with 4.5 mL of water R and 0.5 mL of sodium hydroxide (10 g/L) TS and heat the mixture in a water-bath at 85 °C for 15 minutes.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 250 nm. Maintain the column at a temperature of 30 °C.

Inject 20 μL of solution (3). The test is not valid unless the resolution between the peak due to atazanavir (retention time about 22 minutes) and the peak with a relative retention of about 1.2 is at least 4.
Inject alternately 20 µL each of solutions (1) and (2).

In the chromatograms obtained with test solution (1):

- the area of any peak, other than the principal peak, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);
- the sum of the areas of all peaks, other than the principal peak, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (1.0%). Disregard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).

**Assay**

Dissolve 0.300 g, accurately weighed, in 30 mL of methanol R by sonication for 10 minutes. Then add 30 mL of water and titrate with sodium hydroxide (0.1 mol/L) VS, determining the end-point potentiometrically. Each mL of sodium hydroxide (0.1 mol/L) VS is equivalent to 40.145 mg of C_{38}H_{52}N_{6}O_{7}•H_{2}SO_{4}.

***